Sanofi

Sanofi-A Ventis Deutschland Gmbh

Zentiva K.s.

Hermut Wehlan

Kai Rossen

Christopher Kallus

Hartmut Strobel

Klaus Wirth

Christian Buning

Herman Schreuder

Sven Ruf

Thorsten Sadowski

Guenter Billen

Volker Kraft

Michael Wagner

Andreas Evers

Oliver Plettenburg

Antony Bigot

Simon Gessler

Michael Podeschwa

Veronique Crocq-Stuerga

Alexander Schaefer

Jan Oehme

Vladimír KRÁL

Véronique Crocq-Stuerga

A new process for the preparation of fexofenadine and of related intermediates, which can be used in the preparation of fexofenadine, is provided.

Process for the preparation of fexofenadine and of intermediates used therein

A new process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile is described. This compound can be used for the production of drugs, such as Fexofenadine.

Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile

The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments. 

Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Biaryl-propionic acid derivatives and their use as pharmaceuticals

The invention relates to the salt of naphthalene-1,5-disulfonic acid with (R)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1H-imidazol-4-yl)ethyl propionate, which can be represented by the following structural formula of formula (I), to methods for the production thereof, to drugs containing said salt, and to the use of said drugs to treat diseases that are accompanied by thromboses, embolisms, hypercoagulability, or fibrotic changes.

Salt of (R)-3-(6-amino-pyridin-3-yl)-2-(1-Cyclohexyl-1H-imidazol-4-yl) ethyl propionate

The present invention relates to a process for the preparation of a compound of the formula I,  

Process for the preparation of a compound useful as an inhibitor of TAFIa

The present invention relates to a process for making 6-substituted-1-(2H)-isoquinolinone derivatives of formula (I) wherein R1 and n are as described in the specification. The present invention further relates to novel intermediates which are used in the process according to the invention and to processes for preparing such intermediates.

Process for the preparation of 6-substituted-1-(2H)-isoquinolinones

Growing community of inventors

Frankfurt am Main, Germany

Hermut Wehlan